儿科急性淋巴细胞白血病中CDKN2A/2B基因的临床特征和预后分析:一个回顾性病例控制研究
Shi-Mei Huang1, Hui-Qin Chen2, Li-Ting Liu2
1Children's Medical Center, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, People's Republic of China.
Hematology (Amsterdam, Netherlands)
|December 16, 2024
概括
患有CDKN2A/2B基因缺失的儿科急性淋巴细胞白血病 (ALL) 患者表现出明显的临床特征,但对整体存活率没有显著影响. 这一组的肝积病表明预后较差,突出显示了风险分层的必要性.
科学领域:
- 儿科瘤学 儿科瘤学
- 癌症遗传学 癌症遗传学
- 分子生物学分子生物学
背景情况:
- 在一些儿科急性淋巴细胞白血病 (ALL) 病例中观察到循环素依赖性激酶抑制剂2A/2B (CDKN2A/2B) 基因缺失.
- 了解CDKN2A/2B删除的临床和预后影响对于风险分层至关重要.
研究的目的:
- 分析患有CDKN2A/2B基因缺失的儿科ALL患者的临床特征和预后.
- 研究CDKN2A/2B删除与其他遗传异常和患者结局之间的关联.
主要方法:
- 在SCCLG-ALL-2016协议下治疗的424名儿科ALL患者的回顾性病例控制研究.
- 使用遗传方法分析CDKN2A/2B基因删除 (同卵性和异卵性).
- 与临床特征,遗传标记 (ETV6::RUNX1,IKZF1) 和生存结果 (OS,EFS) 的相关性分析.
主要成果:
- CDKN2A/2B的缺失发生在21.7%的患者中,与年龄较大,肝炎,中枢神经系统白血病 (CNSL) 和T-ALL.相关.
- 缺失的患者与ETV6::RUNX1和IKZF1缺失的同时发生增加.
- 两组之间在5年复发,整体存活率 (OS) 或无事件存活率 (EFS) 上没有发现显著差异.
- 删除组中的肝积病与较差的EFS相关 (P=0.05),被确定为显著的预后因素 (HR=2.306,P=0.013).
结论:
- 儿科ALL中CDKN2A/2B基因缺失与特定的临床和遗传特征有关,但不会独立影响整体存活率.
- 患有CDKN2A/2B删除的儿科ALL的肝积可能意味着预后较差,需要仔细评估风险.
- 综合风险分层对于优化儿科ALL治疗策略至关重要,特别是对于具有特定遗传变异和临床表现的子组.
更多相关视频
09:52A Chromatin Immunoprecipitation Assay to Identify Novel NFAT2 Target Genes in Chronic Lymphocytic Leukemia
Published on: December 4, 2018
7.5K
09:09Preparation of Primary Acute Lymphoblastic Leukemia Cells in Different Cell Cycle Phases by Centrifugal Elutriation
Published on: November 10, 2017
8.2K
相关概念视频
The Retinoblastoma Gene
4.0K
Tumor suppressor genes are normal genes that can slow down cell division, repair DNA mistakes, or program the cells for apoptosis in case of irreparable damage. Hence, they play an essential role in preventing the proliferation of damaged cells.
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
4.0K
Cancer-Critical Genes II: Tumor Suppressor Genes
7.3K
Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
7.3K
M-Cdk Drives Transition Into Mitosis
5.5K
Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
5.5K
Inhibition of Cdk Activity
4.6K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.6K
